News

At Plectonic Biotech, we are committed to pioneering the next generation of DNA-based immunotherapies. Follow our journey as we advance our LOGIBODY platform, secure key partnerships, and move closer to clinical application.

2025 - Strategic Partnership with Sonrai Analytics

Through a new collaboration with Sonrai Analytics, Plectonic Biotech is enhancing the development of its LOGIBODY technology by integrating high-resolution, AI-powered antigen discovery to drive safer, more targeted cancer immunotherapies.

2024 - Expansion of Preclinical Studies

Plectonic Biotech advances its two lead indications through extensive in vivo validation and refines the LOGIBODY platform.

2023 – Plectonic Biotech at Key Industry Events

Our CEO Klaus Wagenbauer is presenting the latest findings and development strategy at PEGS-Europe conferences in Lissabon.

2023 – LOGIBODY Research Published in Nature Nanotechnology

Groundbreaking findings confirm the potential of LOGIBODY technology, demonstrating precise immune activation with reduced side effects.

2023 - Plectonic Biotech Secures SPRIND Funding

The company receives substantial funding from SPRIND to accelerate LOGIBODY preclinical development and establish scalable manufacturing.